Table 6.

Logistic regression analysis of subjects with subclinical hypothyroidism (population-based TSH reference range is used).

	Crude model		Adjusted model
	Odds ratio (95% CI)	P value	Odds ratio (95% CI)	P value
Male
Age (years)
19–29	Reference		Reference
30–39	0.64 (0.25–1.66)	0.656	0.56 (0.20–1.53)	0.254
40–49	0.87 (0.37–2.08)	0.665	0.76 (0.29–2.00)	0.581
50–59	1.10 (0.48–2.56)	0.239	0.81 (0.31–2.15)	0.674
60–69	0.78 (0.28–2.20)	0.940	0.54 (0.16–1.89)	0.336
70 and above	0.39 (0.05–3.09)	0.434	0.27 (0.03–2.07)	0.205
BMI (kg/m2)
<18.5	Reference
≥18.5, <23	0.99 (0.13–7.59)	0.986
≥23, <25	0.97 (0.12–7.71)	0.959
≥25	0.98 (0.13–7.55)	0.986
Region of residencea
Rural	Reference
Urban	0.88 (0.46–1.71)	0.710
Family history of thyroid disease
No
Yes	N/A	N/A
Smoking
No	Reference
Yes	0.74 (0.38–1.45)	0.377	0.73 (0.34–1.58)	0.423
UICRb
Quartile 1	Reference		Reference
Quartile 2	2.27 (0.84–6.16)	0.749	2.57 (0.92–7.13)	0.071
Quartile 3	3.24 (1.21–8.63)	0.312	3.75 (1.34–10.51)	0.012
Quartile 4	5.14 (2.06–12.83)	0.002	5.80 (2.22–15.15)	<0.001
Anti-TPO Ab
Absence	Reference		Reference
Presence	5.47 (2.42–12.33)	<0.001	5.65 (2.33–13.71)	<0.001
CKD stage
Stage1, 2	Reference
Stage 3, 4, 5	0.70 (0.17–2.96)	0.629
Female
Age (years)
19–29	Reference		Reference
30–39	0.86 (0.374–2.01)	0.162	0.67 (0.28–1.63)	0.379
40–49	1.60 (0.75–3.44)	0.487	1.17 (0.53–2.59)	0.694
50–59	2.74 (1.28–5.88)	0.002	1.68 (0.76–3.74)	0.202
60–69	1.19 (0.49–2.85)	0.668	0.73 (0.28–1.89)	0.519
70–	1.31 (0.33–5.20)	0.963	0.97 (0.25–3.69)	0.960
BMI (kg/m2)
<18.5	Reference
≥18.5, <23	1.10 (0.43–2.84)	0.871
≥23, <25	1.36 (0.50–3.71)	0.419
≥25	1.11 (0.41–2.99)	0.920
Region of residencea
Rural	Reference
Urban	2.18 (1.19–3.99)	0.011
Family history of thyroid disease
No	Reference
Yes	0.52 (0.15–1.82)	0.306
Smoking
No	Reference
Yes	0.54 (0.23–1.26)	0.155	0.60 (0.25–1.40)	0.237
UICRb
Quartile 1	Reference		Reference
Quartile 2	1.45 (0.63–3.37)	0.921	1.40 (0.59–3.29)	0.445
Quartile 3	1.34 (0.64–2.80)	0.621	1.31 (0.61–2.81)	0.493
Quartile 4	2.52 (1.30–4.88)	<0.001	2.67 (1.35–5.26)	0.005
Anti-TPO Ab
Absence	Reference		Reference
Presence	5.49 (3.26–9.22)	<0.001	5.33 (3.19–8.90)	<0.001
CKD stage
Stage 1, 2	Reference
Stage 3, 4, 5	0.28 (0.06–1.24)	0.093

*Data are presented OR (95% CI), statistics were carried out using logistic regression; ^aclassification of the area of residence is classified according to the administrative division of Korea; ^biodine intake status was evaluated by urine iodine creatinine ratio, quartile 1: <Q1 (141.53203438), quartile 2: ≥Q1 and <Q2 (281.81447737), quartile 3: ≥Q2 and <Q3 (664.64655625), quartile 4: ≥Q3.

N/A, not available.